BridgeBio Oncology Therapeutics (BBOT) Competitors

$8.51 0.00 (0.00%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$8.20 -0.32 (-3.70%)

As of 05/15/2026 07:43 PM Eastern

BBOT vs. IVT, AAMI, GCMG, NTST, and GNL

Should you buy BridgeBio Oncology Therapeutics stock or one of its competitors? MarketBeat compares BridgeBio Oncology Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BridgeBio Oncology Therapeutics include InvenTrust Properties (IVT), Acadian Asset Management (AAMI), GCM Grosvenor (GCMG), NETSTREIT (NTST), and Global Net Lease (GNL). These companies are all part of the "trading" industry.

How does BridgeBio Oncology Therapeutics compare to InvenTrust Properties?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and InvenTrust Properties (NYSE:IVT) are both trading companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

InvenTrust Properties has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than InvenTrust Properties, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$1.52	N/A
InvenTrust Properties	$299.17M	8.16	$111.42M	$1.41	22.22

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. Comparatively, 61.7% of InvenTrust Properties shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Comparatively, 0.7% of InvenTrust Properties shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, BridgeBio Oncology Therapeutics had 8 more articles in the media than InvenTrust Properties. MarketBeat recorded 8 mentions for BridgeBio Oncology Therapeutics and 0 mentions for InvenTrust Properties. InvenTrust Properties' average media sentiment score of 1.02 beat BridgeBio Oncology Therapeutics' score of 0.83 indicating that InvenTrust Properties is being referred to more favorably in the news media.

Company	Overall Sentiment
BridgeBio Oncology Therapeutics	Positive
InvenTrust Properties	Positive

BridgeBio Oncology Therapeutics has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, InvenTrust Properties has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

InvenTrust Properties has a net margin of 35.66% compared to BridgeBio Oncology Therapeutics' net margin of 0.00%. InvenTrust Properties' return on equity of 6.10% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	N/A	N/A
InvenTrust Properties	35.66%	6.10%	3.95%

BridgeBio Oncology Therapeutics currently has a consensus target price of $25.00, indicating a potential upside of 193.77%. InvenTrust Properties has a consensus target price of $33.20, indicating a potential upside of 5.97%. Given BridgeBio Oncology Therapeutics' higher possible upside, equities analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than InvenTrust Properties.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
InvenTrust Properties	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

InvenTrust Properties beats BridgeBio Oncology Therapeutics on 11 of the 14 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Acadian Asset Management?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Acadian Asset Management (NYSE:AAMI) are both trading companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

BridgeBio Oncology Therapeutics currently has a consensus target price of $25.00, indicating a potential upside of 193.77%. Acadian Asset Management has a consensus target price of $62.00, indicating a potential downside of 9.76%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Acadian Asset Management.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Acadian Asset Management	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20

Acadian Asset Management has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Acadian Asset Management, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$1.52	N/A
Acadian Asset Management	$563.70M	4.34	$80M	$2.35	29.23

BridgeBio Oncology Therapeutics has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, Acadian Asset Management has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

In the previous week, BridgeBio Oncology Therapeutics had 4 more articles in the media than Acadian Asset Management. MarketBeat recorded 8 mentions for BridgeBio Oncology Therapeutics and 4 mentions for Acadian Asset Management. Acadian Asset Management's average media sentiment score of 1.39 beat BridgeBio Oncology Therapeutics' score of 0.83 indicating that Acadian Asset Management is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Oncology Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acadian Asset Management	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. Comparatively, 98.7% of Acadian Asset Management shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Comparatively, 22.6% of Acadian Asset Management shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Acadian Asset Management has a net margin of 13.78% compared to BridgeBio Oncology Therapeutics' net margin of 0.00%. Acadian Asset Management's return on equity of 185.73% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	N/A	N/A
Acadian Asset Management	13.78%	185.73%	19.17%

Summary

Acadian Asset Management beats BridgeBio Oncology Therapeutics on 10 of the 15 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to GCM Grosvenor?

GCM Grosvenor (NASDAQ:GCMG) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both trading companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

100.0% of GCM Grosvenor shares are owned by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. 70.7% of GCM Grosvenor shares are owned by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

GCM Grosvenor has a net margin of 9.05% compared to BridgeBio Oncology Therapeutics' net margin of 0.00%. GCM Grosvenor's return on equity of 222.78% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GCM Grosvenor	9.05%	222.78%	18.36%
BridgeBio Oncology Therapeutics	N/A	N/A	N/A

GCM Grosvenor has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than GCM Grosvenor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GCM Grosvenor	$557.57M	3.86	$45.37M	$0.45	23.67
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$1.52	N/A

GCM Grosvenor has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market.

GCM Grosvenor presently has a consensus target price of $15.50, indicating a potential upside of 45.54%. BridgeBio Oncology Therapeutics has a consensus target price of $25.00, indicating a potential upside of 193.77%. Given BridgeBio Oncology Therapeutics' higher possible upside, analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than GCM Grosvenor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GCM Grosvenor	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, BridgeBio Oncology Therapeutics had 3 more articles in the media than GCM Grosvenor. MarketBeat recorded 8 mentions for BridgeBio Oncology Therapeutics and 5 mentions for GCM Grosvenor. BridgeBio Oncology Therapeutics' average media sentiment score of 0.83 beat GCM Grosvenor's score of 0.80 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GCM Grosvenor	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Oncology Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GCM Grosvenor beats BridgeBio Oncology Therapeutics on 11 of the 15 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to NETSTREIT?

NETSTREIT (NYSE:NTST) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap trading companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. 0.7% of NETSTREIT shares are owned by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

NETSTREIT has a net margin of 5.29% compared to BridgeBio Oncology Therapeutics' net margin of 0.00%. NETSTREIT's return on equity of 0.78% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NETSTREIT	5.29%	0.78%	0.43%
BridgeBio Oncology Therapeutics	N/A	N/A	N/A

NETSTREIT has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than NETSTREIT, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NETSTREIT	$195.01M	10.21	$6.90M	$0.13	157.43
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$1.52	N/A

NETSTREIT has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market.

NETSTREIT presently has a consensus target price of $22.25, indicating a potential upside of 8.72%. BridgeBio Oncology Therapeutics has a consensus target price of $25.00, indicating a potential upside of 193.77%. Given BridgeBio Oncology Therapeutics' higher possible upside, analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than NETSTREIT.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NETSTREIT	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.80
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, BridgeBio Oncology Therapeutics had 3 more articles in the media than NETSTREIT. MarketBeat recorded 8 mentions for BridgeBio Oncology Therapeutics and 5 mentions for NETSTREIT. NETSTREIT's average media sentiment score of 0.85 beat BridgeBio Oncology Therapeutics' score of 0.83 indicating that NETSTREIT is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NETSTREIT	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Oncology Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NETSTREIT beats BridgeBio Oncology Therapeutics on 11 of the 15 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Global Net Lease?

Global Net Lease (NYSE:GNL) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap trading companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Global Net Lease's net margin of -8.72%. BridgeBio Oncology Therapeutics' return on equity of 0.00% beat Global Net Lease's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Global Net Lease	-8.72%	-2.90%	-1.07%
BridgeBio Oncology Therapeutics	N/A	N/A	N/A

61.2% of Global Net Lease shares are owned by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. 0.6% of Global Net Lease shares are owned by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Global Net Lease has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market.

BridgeBio Oncology Therapeutics has lower revenue, but higher earnings than Global Net Lease. Global Net Lease is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Net Lease	$495.29M	3.95	-$225.46M	-$0.40	N/A
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$1.52	N/A

In the previous week, BridgeBio Oncology Therapeutics had 4 more articles in the media than Global Net Lease. MarketBeat recorded 8 mentions for BridgeBio Oncology Therapeutics and 4 mentions for Global Net Lease. BridgeBio Oncology Therapeutics' average media sentiment score of 0.83 beat Global Net Lease's score of 0.43 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Global Net Lease	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Oncology Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Global Net Lease presently has a consensus target price of $10.40, indicating a potential upside of 12.62%. BridgeBio Oncology Therapeutics has a consensus target price of $25.00, indicating a potential upside of 193.77%. Given BridgeBio Oncology Therapeutics' higher possible upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Global Net Lease.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Net Lease	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

BridgeBio Oncology Therapeutics beats Global Net Lease on 9 of the 15 factors compared between the two stocks.

Get BridgeBio Oncology Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBOT vs. The Competition

Export

Metric	BridgeBio Oncology Therapeutics	Investment Offices Industry	Financial Sector	NASDAQ Exchange
Market Cap	$681.71M	$319.81M	$5.74B	$12.47B
Dividend Yield	N/A	N/A	5.24%	5.28%
P/E Ratio	-5.60	1.28	15.93	25.23
Price / Sales	N/A	234.56	1,025.06	83.05
Price / Cash	N/A	134.32	91.01	56.04
Price / Book	1.83	347.49	6.59	6.91
Net Income	-$134.04M	-$66.73M	$1.15B	$334.11M
7 Day Performance	11.10%	0.89%	-0.22%	0.01%
1 Month Performance	-7.70%	2.17%	1.23%	1.17%
1 Year Performance	N/A	6.54%	18.17%	30.68%

BridgeBio Oncology Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBOT BridgeBio Oncology Therapeutics	1.9604 of 5 stars	$8.51 flat	$25.00 +193.8%	N/A	$681.71M	N/A	N/A	N/A	News Coverage Earnings Report Analyst Downgrade
IVT InvenTrust Properties	2.9698 of 5 stars	$31.38 -0.9%	$33.20 +5.8%	+10.7%	$2.45B	$307.98M	22.25	110	Positive News
AAMI Acadian Asset Management	3.3872 of 5 stars	$68.56 +3.1%	$62.00 -9.6%	+125.2%	$2.44B	$563.70M	29.17	350	Positive News
GCMG GCM Grosvenor	4.4733 of 5 stars	$11.36 +1.8%	$15.00 +32.0%	-15.3%	$2.30B	$557.57M	30.70	530
NTST NETSTREIT	2.3404 of 5 stars	$20.68 +1.6%	$22.10 +6.8%	+30.3%	$2.01B	$192.67M	159.12	30	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBOT) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Oncology Therapeutics (BBOT) Competitors

BBOT vs. IVT, AAMI, GCMG, NTST, and GNL

How does BridgeBio Oncology Therapeutics compare to InvenTrust Properties?

Summary

How does BridgeBio Oncology Therapeutics compare to Acadian Asset Management?

Summary

How does BridgeBio Oncology Therapeutics compare to GCM Grosvenor?

Summary

How does BridgeBio Oncology Therapeutics compare to NETSTREIT?

Summary

How does BridgeBio Oncology Therapeutics compare to Global Net Lease?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT vs. The Competition

BridgeBio Oncology Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Oncology Therapeutics (BBOT) Competitors

BBOT vs. IVT, AAMI, GCMG, NTST, and GNL

How does BridgeBio Oncology Therapeutics compare to InvenTrust Properties?

Which has higher valuation and earnings, BBOT or IVT?

Do insiders and institutionals hold more shares of BBOT or IVT?

Does the media refer more to BBOT or IVT?

Which has more risk & volatility, BBOT or IVT?

Is BBOT or IVT more profitable?

Do analysts prefer BBOT or IVT?

Summary

How does BridgeBio Oncology Therapeutics compare to Acadian Asset Management?

Do analysts prefer BBOT or AAMI?

Which has higher valuation and earnings, BBOT or AAMI?

Which has more risk & volatility, BBOT or AAMI?

Does the media refer more to BBOT or AAMI?

Do insiders and institutionals hold more shares of BBOT or AAMI?

Is BBOT or AAMI more profitable?

Summary

How does BridgeBio Oncology Therapeutics compare to GCM Grosvenor?

Do insiders & institutionals hold more shares of GCMG or BBOT?

Is GCMG or BBOT more profitable?

Which has higher valuation and earnings, GCMG or BBOT?

Which has more risk and volatility, GCMG or BBOT?

Do analysts rate GCMG or BBOT?

Does the media prefer GCMG or BBOT?

Summary

How does BridgeBio Oncology Therapeutics compare to NETSTREIT?

Do insiders & institutionals hold more shares of NTST or BBOT?

Is NTST or BBOT more profitable?

Which has higher valuation and earnings, NTST or BBOT?

Which has more risk and volatility, NTST or BBOT?

Do analysts rate NTST or BBOT?

Does the media prefer NTST or BBOT?

Summary

How does BridgeBio Oncology Therapeutics compare to Global Net Lease?

Is GNL or BBOT more profitable?

Do institutionals & insiders believe in GNL or BBOT?

Which has more volatility & risk, GNL or BBOT?

Which has stronger valuation & earnings, GNL or BBOT?

Does the media prefer GNL or BBOT?

Do analysts rate GNL or BBOT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT vs. The Competition

BridgeBio Oncology Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools